ANG LI to Treatment Outcome
This is a "connection" page, showing publications ANG LI has written about Treatment Outcome.
Connection Strength
0.203
-
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Leuk Res. 2020 02; 89:106298.
Score: 0.051
-
Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. J Thromb Haemost. 2019 12; 17(12):2141-2151.
Score: 0.050
-
External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J Thromb Haemost. 2018 01; 16(1):164-169.
Score: 0.044
-
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer. 2020 03 15; 126(6):1208-1216.
Score: 0.013
-
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Adv. 2019 10 22; 3(20):3062-3069.
Score: 0.013
-
Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv. 2019 05 14; 3(9):1512-1518.
Score: 0.012
-
Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost. 2017 07; 15(7):1322-1333.
Score: 0.011
-
Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative. Br J Haematol. 2015 Dec; 171(5):836-44.
Score: 0.009